anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: To observe the curative efficacy of auricular comprehensive therapy on menstrual migraine(MM) and its effect on serum prostaglandin F2α(PGF2α), prostaglandin E2(PGE2) contents and ratio, so as to explore its possible mechanism.
METHODS: A total of 66 patients with MM of liver-fire syndrome were randomly divided into observation group (33 cases, 2 cases dropped off) and control group (33 cases, 2 cases dropped off), and 20 healthy women were included in the normal group. Patients in the control group were given flunarizine hydrochloride capsules orally, twice a day, for 3 consecutive weeks. Patients in the observation group were treated with auricular comprehensive therapy, starting 2-5 days before menstrual cramps, once a week, for a total of 3 weeks. The visual analogue scale (VAS) and migraine score were evaluated before and after treatment, and follow-up for 1 and 2 menstrual cycles. Serum PGF2α and PGE2 contents were measured before and after treatment, and the PGF2α/PGE2 ratio was calculated. The clinical effective rates in the two groups were calculated.
RESULTS: After treatment and follow-up for 1 and 2 menstrual cycles, the VAS scores, headache degree, the frequency and duration of headache attacks, as well as accompanying symptoms of the observation and control groups were lower than those before treatment(P<0.05), and those of the observation group was lower than those of the control group(P<0.05). Before treatment, the PGF2α contents in the observation and control group were significantly higher(P<0.05), while the PGE2 contents lower(P<0.05) and PGF2α/PGE2 ratio higher(P<0.05) than those in the normal group. After treatment, the serum PGF2α contents in the observation and control group were significantly reduced compared with which before treatment(P<0.05), and were lower in the observation group than that in the control group (P<0.05). The serum PGE2 contents in the observation and control groups were significantly increased after treatment compared with which before treatment(P<0.05), with the contents in the observation group higher than that in the control group(P<0.05). The serum PGF2α/PGE2 ratio in the observation and control group was significantly reduced after treatment compared with which before treatment(P<0.05), with the control group higher than the normal group(P<0.05), and the observation group lower than the control group(P<0.05). The clinical effective rate of the observation group was 93.5% (29/31), and that of the control group was 77.4% (24/31). The effective rate of the observation group was significantly higher than that of the control group(P<0.05).
CONCLUSIONS: The curative efficacy of auricular comprehensive therapy on MM with liver-fire syndrome is significantly better than that of oral flunarizine hydrochloride capsules, especially in relieving hea-daches, reducing the frequency and duration of headache attacks, as well as accompanying symptoms. Its mechanism may be related to regulating the abnormal PGF2α and PGE2 contents of patients and reducing the ratio of PGF2α/PGE2.
PURPOSE:To provide the titled preparation containing an encapsulated composition obtained by compounding an active component with an emulsion base consisting of a hydrophilic substance, an oily substance and a substance which is solid at room temperature, and able to control the dissolution time in body fluid by varying the relative ratios of the three components of the above emulsion base. CONSTITUTION:A mixture of (A) an active component and (B) an emulsion base consisting of a hydrophilic substance (e.g. macrogol, sugar, polyhydric alcohol, etc.), an oily substance (e.g. animal or vegetable food oil) and a substance which is solid at room temperature (e.g. beeswax, unsaponified soybean oil, etc.) is used as a content and encapsulated with gelatin to obtain the objective gelatin encapsulated preparation. The dissolution time of the capsule in body fluid can be freely controlled by varying the compositional ratios of the components of the emulsion base. The dissolution time is shortened by increasing the ratio of the hydrophilic substance in the emulsion base and is prolonged by increasing the ratio of the oily substance.
This multi-center randomized controlled trial, included patients with chronic abdominal pain likely to be caused by adhesions from previous abdominal surgery. Chronic abdominal pain was defined as continues or intermittent abdominal pain of at least six months' duration. After excluding other pathology (see exclusion criteria) included patients underwent a diagnostic laparoscopy to confirm the adhesions and to exclude serious morbidity not visible with other diagnostics. If during laparoscopy adhesions were the only pathology present, patients were randomly assigned either to laparoscopic adhesiolysis or no treatment. For the randomization and surgical procedures the investigators refer to the original article. Patients were unaware of their treatment assignment and the outcome assessment was blinded. Abdominal pain and quality of life (QOL) were assessed pre-operatively and at 3, 6 and 12 months of follow-using a visual analog scale (VAS), verbal rating pain change score (VRCS) and the short form 36 (SF-36). After twelve months randomization was disclosed and placebo group patients with persisting abdominal pain could request laparoscopic adhesiolysis. After twelve year follow-up pain, QOL, medical history and analgesic intake were analyzed to assess the long term effects of laparoscopic adhesiolysis.
In population Ⅴ, 40 subjects were considered to be recombinant mycobacterium tuberculosis fusion protein (EC) was positive. The type Ⅴ population were injected 3 dose of High-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02) and 3 dose of Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo.The first, third, and sixth doses of the subjects were High-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02), and the second, fourth, and fifth doses were Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo. Each dose is 2 weeks apart.
The second group is treated according to the HAI5 schedule, developed by the radiotherapy department of Ghent University Hospital. In this schedule, at least 1 day of rest is scheduled between each treatment session, so the treatment is administered over 10-14 days.
Preschool children with wheezing disorders pose diagnostic and therapeutic challenges and consume substantial healthcare resources. Peripheral eosinophil blood count (EBC) has been proposed as a potential indicator for future asthma development. This review by the European Academy of Allergy and Clinical Immunology (EAACI) Preschool Wheeze Task Force aimed to provide systematic evidence for the association between increased EBC and the risk of future asthma, as well as to identify potential cutoff values. In February 2023, a search of PubMed, EMBASE, and Cochrane Library databases was conducted to identify studies comparing EBCs in preschool children with wheezing who continued to wheeze later in life and those who did not. Included observational studies focused on children aged <6 years with a wheezing disorder, assessment of their EBCs, and subsequent asthma status. No language or publication date restrictions were applied. Among the initial 3394 studies screened, 10 were included in the final analysis, involving 1225 patients. The data from these studies demonstrated that high EBC in preschool children with wheezing is associated with future asthma development, with odds ratios of 1.90 (95% CI: 0.45-7.98, p = .38), 2.87 (95% CI: 1.38-5.95, p < .05), and 3.38 (95% CI: 1.72-6.64, p < .05) for cutoff values in the <300, 300-449, and ≥450 cells/μL ranges, respectively. Defining a specific cutoff point for an elevated EBC lacks consistency, but children with EBC >300 cells/μL are at increased risk of asthma. However, further research is needed due to the limitations of the included studies. Future investigations are necessary to fully elucidate the discussed association.
Individual planning (also known as implementation intentions or action and coping planning) is a regulatory strategy, which refers to making plans on when, where, and how to perform an intended behavior. In dyadic planning, a target person is setting plans together with a partner on when, where, and how the target person will individually engage in behavior change. The concept of dyadic planning differs from the conceptualization of collaborative plans, where two individuals make plans on how to enact a behavior together.

The study will evaluate the effects of a short-term planning intervention. The intervention includes a total of six sessions: two face-to-face sessions with the experimenter (delivered over two weeks) and three sessions delivered over phone (over the following three weeks), one face-two-face session (delivered at one month after the third session delivered over the phone). The delivery has an individual format (the experimenter + the dyad). The total time from first to sixth session is 2 months. The setting for the interventions will include schools (school nurse office) or/and participant's home. The same format, schedule, delivery, and setting will be used for conducting active control group procedures.
Subjects will be randomized into one of three cohorts (360, 1,080, and 1,440 mg) to receive a daily oral dose for 14 consecutive days. Each cohort will have 12 subjects on active drug and 4 subjects on placebo.
Antibiotics administration can sometimes be delayed in the emergency department (ED) environment, where antibiotics are frequently ordered in electronic medical record systems as a one-time dose and the second dose is delayed or missed. This has been described in the literature, a 2017 article in Critical Care Medicine noted in a single academic center that 33% of sepsis cases had 2nd-dose-antibiotic delays greater than 25% of the recommend interval and this was associated with significantly increased hospital mortality (OR 1.61) and mechanical ventilation (OR 2.44).

An Epic Best Practice Advisory (BPA) was created by the Mass General Brigham eCare Decision Support team to address this patient safety concern. The BPA alerts providers in the ED or ED Observation when the next dose of broad-spectrum antibiotic dose is due for a patient if no future administration has been ordered, based on patient characteristics (such as renal function) and antibiotic selection. The objective of this study is to analyze the impact of this BPA on our performance in terms of on-time antibiotics through a randomized controlled trial. Patients whose medical record number (MRN) are odd will be assigned to the treatment group, while those whose MRNs are even will be assigned to the control group. The BPA will only be displayed to the patient's providers for the treatment group. We will then compare the performance of on-time antibiotics between the groups and the resulting impact on patient outcomes, such as overall hospital length of stay, admission to the intensive care unit (ICU), and in-hospital mortality.
A system for orthodontic treatment planning. The system comprises a processor and memory. Computer-program instructions cause the system to display a user interface on a display. The user interface is for a user to input a prescription for treatment of the patient. The user interface provides a plurality of commands for selection. Each command is a one-word instruction, a two-word instruction, or a three-word instruction based on orthodontic nomenclature. The system receives selected two or more of the plurality of commands into the prescription for treatment. The two or more selected commands are to be applied according to a predetermined protocol to the patient's teeth. A database is configured to receive the prescription for treatment of the patient and to contain a plurality of other prescriptions for treatment of other patients. The database is configured to receive a plurality of other prescriptions from a plurality of users of the system.
FIELD: microbiology. SUBSTANCE: method deals with the impact of a composition containing an antibiotic, a surface-active substance (SAS) and a solvent upon microorganisms. The ratio of components is used to provide developing the antibiotic- bearing associates of the surface-active substances. As for an antibiotic, it is chosen out of a group: oxytetracycline, levomycetin, penicillin. Antibiotic content is taken regarding SAS in a molar ratio (0.2-0.3): 1. EFFECT: higher efficiency in using antibiotics to inhibit or inactivate microorganisms' growth, at sterilization of different media, among them. 1 cl, 2 ex
The main part of RES group session will include free weights, weight machines and calisthenics. Loads will be set and adjusted based on 1 repetition maximum (1RM) method (details are described in Table 2). Exercises will be standardized but exercises may be adapted according to participants limitations. For RES group, the intervention was divided in 2 periods: a) 3- weeks adaptation phase (7-10 exercises; 1-2 sets; 15-20 reps; 40-60% 1RM); b) 9-weeks training phase (8 exercises; 3 sets; 6-12 reps; 70% 1RM; intensity measured by the rate of perceived exertion (RPE) 3-5 on category ratio 10 (CR10) scale progressing to RPE 6-8; resting 60-120 s between sets; 3-5 min between exercises) as recommended (29). Each session will aim at two anatomical regions (upper limbs, torso, back, lower limbs).
Cephapirin derivatives (chlorohydrate, p-toluene sulfonate, and β-naphtalene sulfonate) were prepd. by several stepwise reactions. 7- ACA was reacted with bromophtalide at 0-70≰  in the presence of dimethylsulfoxide, dimethylacetamide, or formamide. The synthesized 7-ACA ester was reacted with chloride chlorohydrate of 4-pyridyl- thioacetate, washed with an acidic solution (pH 1-4), and dried under a vacuum and at low temp. to give cephapirin derivatives. The bactericidal activity of cephapirin derivatives was expressed.
A broad-based remediation mechanism against MRFs and alternative fecal indicators such as multidrug resistant  Pseudomonas aeruginosa , including nanotechnology formulations and methodologies that may be used to develop novel mitigation strategies against certain drug resistant bacterial strains. The current invention relates to mitigation of drug resistant bacteria, for example in hospitals and in food animals, and to the identification. The invention uses hybrid nanomaterials comprising oligo-chitosan and zinc oxide formulated as nanoparticles and micelles. The invention also relates to the treatment of multi-drug resistant biofilms which mimic in vivo conditions. The inventors unexpectedly found unique properties of very small oligomers of chitosan that effectively mitigate MRF and alternative resistant strain-induced illnesses without compromising the balance of the beneficial flora in the physiological and ecological microenvironments. The combination of chitosan with zinc oxide demonstrated synergistic and unexpected effects in treating multi-drug resistant pathogens.
PURPOSE: To obtain a lipid metabolism improver comprising hesperetin and/or naringenin as an active ingredient. CONSTITUTION: This lipid metabolism improver comprises hesperetin of formula I and naringenin of formula II as active ingredients and is administered as it is or 10-95% of as the lipid metabolism improver by containing its 10-95% in a medicine carrier based on the all components. The compound of formula I and that of formula II have each a lowering action on cholesterol in blood and are effective for treating and preventing especially hypercholesterolemia, arteriosclerosis and cardiac infarction. The lipid metabolism improver can be administered orally, interstitially, percutaneously or per rectum and preferably orally. A daily dose is 0.01-50g, preferably 0.1-1g per adult.  The compounds of formula I and formula II are well-known and the compound of formula I is extracted from periderm of a citrus fruit such as tangerine or orange and the compound of formula II from periderm of Citrus natudaidai, grape fruit, etc.
The invention provides mint rice wine which is prepared from the following raw materials in parts by weight: 300 to 330 parts of sticky rice, 10 to 15 parts of sorghum, 20 to 30 parts of black fungus powder, 4 to 5 parts of distilling yeast, 30 to 40 parts of towel gourd, 20 to 30 parts of zizania aquatica, 40 to 50 parts of milk, 10 to 15 parts of mint, 8 to 10 parts of platycodon grandiflorum, 6 to 8 parts of agastache rugosus, 3 to 4 parts of flos magnoliae liliflorae and the like. The invention discloses the mint rice wine and a preparation method thereof. The black fungus powder, the towel gourd and the like are added, so that the mint rice wine has functions of expelling toxin, clearing heat and cooling blood, moistening skin and beautifying face and the like, i.e., the mint rice wine is nutritional and healthy. The mint, the platycodon grandiflorum, the agastache rugosus, the flos magnoliae liliflorae and other extracts of traditional Chinese medicinal materials are added, so that the mint rice wine has the functions of dispelling wind and heat, clearing heat and removing toxicity and the like. During a secondary fermentation process, the chrysanthemum powder is added, so that the rice wine has subtle chrysanthemum fragrance. Thus, the rice wine is popular among people.
CONTEXT: Papillary thyroid microcarcinoma (PTMC) is the most common type of thyroid cancer. It has been shown that lymph node metastasis is associated with poor prognosis in patients with PTMC.
OBJECTIVE: We aim to characterize the PTMC transcriptome landscape and identify the candidate transcripts that are associated with lateral neck lymph node metastasis of PTMC.
METHODS: We performed full-length transcriptome sequencing in 64 PTMC samples. Standard bioinformatic pipelines were applied to characterize and annotate the full-length expression profiles of 2 PTMC subtypes. Functional open reading frame (ORF) annotation of the known and novel transcripts were predicted by HMMER, DeepLoc, and DeepTMHMM tools. Candidate transcripts associated with the pN1b subtype were identified after transcript quantification and differential gene expression analyses.
RESULTS: We found that skipping exons accounted for the more than 27.82% of the alternative splicing events. At least 42.56% of the discovered transcripts were novel isoforms of annotated genes. A total of 39 193 ORFs in novel transcripts and 18 596 ORFs in known transcripts were identified. Distribution patterns of the characterized transcripts in functional domain, subcellular localization, and transmembrane structure were predicted. In total, 1033 and 1204 differentially expressed genes were identified in the pN0 and pN1b groups, respectively. Moreover, novel isoforms of FRMD3, NOD1, and SHROOM4 were highlighted for their association with pN1b subtype.
CONCLUSION: Our data provided the global transcriptome landscape of PTMC and also revealed the novel isoforms that associated with PTMC aggressiveness.
<P>PROBLEM TO BE SOLVED: To obtain a medicine composition which treats JC virus infected diseases, e.g., progressive multifocal leukoencephalopathy (PML) by inhibiting expression of agnoprotein and suppressing proliferation of JC virus, a polynucleotide therefor and a use thereof.  <P>SOLUTION: The medicine composition for treating JC virus infected cells by an RNAi (RNA interference) method comprises using a short interfering RNA (siRNA) against a gene encoding JC virus agnoprotein. The polynucleotide is an active ingredient therefor. The medicine composition for treating JC virus infected diseases comprises a short interfering RNA (siRNA) against a gene encoding JC virus agnoprotein or a gene forming the siRNA and a pharmaceutically permissible carrier. The polynucleotide therefor is obtained. The gene is used for producing the medicine composition.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Patients with suspected NPH (triad of cognitive dysfunction, urine incontinence of urge type, abnormal gait) are admitted to the neurosurgical department for intracranial pressure monitoring for 24 hours. The following day an infusiontest is performed, where data is collected.
Recent studies have shown that the extramuscular connective tissue (ECT) is thickened and stiffened in delayed onset muscle soreness (DOMS). However, contrarily to the normal population, severe DOMS is rare in athletes or highly trained individuals. The present randomized, controlled trial therefore aimed to investigate pain as well as microcirculation and stiffness of the ECT and the erector spinae muscle following submaximal eccentric trunk extension exercise not causing DOMS. The effect of manual treatment by a therapist (myofascial release; MFR) on these parameters was to be studied. Trained healthy participants (n = 21; 31.3 ± 9.6 years; > 4 h exercise per week) performed submaximal eccentric exercise of the trunk extensors. One group was manually treated (n = 11), while the other group (n = 10) received placebo treatment with sham laser therapy. Stiffness of the ECT and the erector spinae muscle (shear wave elastography), microcirculation (white light and laser Doppler spectroscopy), palpation pain (100 mm visual analogue scale, VAS) and pressure pain threshold (indentometry, PPT) were assessed before (t0), 24 h (t24) and 48 h (t48) after conditions. Erector spinae muscle stiffness increased after eccentric exercise from t0 to t24 (0.875 m/s) and from t0 to t48 (0.869 m/s). After MFR, erector spinae muscle stiffness decreased in contrast to placebo treatment at t24 (-0.66 m/s), while ECT stiffness remained unchanged. Oxygen saturation increased (17-20.93%) and relative haemoglobin decreased (-9.1 - -12.76 AU) after eccentric exercise and MFR differed from placebo treatment at t48 (-3.71 AU). PPT differed after MFR from placebo treatment at t48 (20.69 N/mm), while VAS remained unchanged. Multiple linear regression showed that ECT stiffness and group membership predicted erector spinae muscle stiffness. MFR could have a positive effect on pain, microcirculation and muscle stiffness after submaximal eccentric exercise, suggesting better recovery, which needs to be confirmed by future work.
<P>PROBLEM TO BE SOLVED: To provide an environmentally closed cell processing device, for the aseptic processing of blood cells.  <P>SOLUTION: The present invention is directed to the environmentally closed cell processing device, for the aseptic processing of blood cells. The device includes a continuous flow centrifuge, fluid reservoirs and fluid handling systems. Blood cells are processed by the present device, to remove their immunodominant antigens. Seroconverted cells and methods of treating subjects with these cells are also described.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Patients will continue to receive treatment as usual from their primary care doctor. Patients in this arm will also receive a free mobile phone for the 12 weeks of the intervention.
IPC will be administered to the upper limb using cuff inflation pressures of 200 mmHg or 60mm Hg above the systolic BP (whichever is higher). Four cycles of cuff inflation each lasting 5 min in duration followed by a 5-min period of cuff deflation will be applied.